clinical trial · NCT07412704
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Bristol-Myers Squibb·phase2·not yet recruiting·n = 84
Arthritis, RheumatoidBMS-986528
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
started
May 28, 2026
primary completion
Oct 30, 2029
completion
Sep 2, 2030
last updated
Feb 23, 2026
official title
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol